Section 301 tariffs and exclusions
Healthcare supply chain, resiliency, product continuity, and domestic manufacturing.
Issues regarding medical device sterilization.
Trade-related healthcare supply chain and resiliency issues
Duration: April 1, 2012
to
April 1, 2013
General Issues: Miscellaneous Tariff Bills , Health Issues , Environmental/Superfund , Trade (Domestic & Foreign) , Manufacturing
Spending: about $3,340,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB), Homeland Security - Dept of (DHS), Commerce - Dept of (DOC), U.S. Trade Representative (USTR), Small Business Administration (SBA), White House Office, State - Dept of (DOS), Food & Drug Administration (FDA),, Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Robert Calia
Confidential Assistant, U.S. Department of Commerce
Confidential Assistant, Department of Commerce
Aaron Winters
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Medline Industries, LP had in-house lobbyists. The report was filed on April 19.
Original Filing: 301565513.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency, product continuity, and domestic manufacturing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Issues regarding medical device sterilization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Trade-related healthcare supply chain and resiliency issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Homeland Security - Dept of (DHS)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, Medline Industries, LP had in-house lobbyists. The report was filed on Jan. 17.
Original Filing: 301526866.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency, product continuity, and domestic manufacturing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Trade-related healthcare supply chain and resiliency issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Homeland Security - Dept of (DHS)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Medline Industries, LP had in-house lobbyists. The report was filed on Oct. 12, 2023.
Original Filing: 301499951.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency, product continuity, reauthorization of the Pandemic and All-Hazards Preparedness and Response Act concerning domestic manufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Trade-related healthcare supply chain and resiliency issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Homeland Security - Dept of (DHS)
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Medline Industries, LP had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301484244.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives Commerce - Dept of (DOC) U.S. Trade Representative (USTR) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency, product continuity and issues surrounding medical device reprocessing, minimum staffing requirements for skilled nursing facilities, S. 1749/H.R. 3227 - the Ensuring Seniors' Access to Quality Care Act regarding certified nursing assistant training, H.R. 468 - Building Americas Health Care Workforce Act regarding emergency waivers, S. 495/H.R. 1815 - Expanding Veterans Options for Long Term Care Act regarding a long-term care pilot program, reauthorization of the Pandemic and All-Hazards Preparedness and Response Act concerning domestic manufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Commerce - Dept of (DOC) Food & Drug Administration (FDA)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Commerce - Dept of (DOC) Food & Drug Administration (FDA)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, Medline Industries, LP had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301460948.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives Commerce - Dept of (DOC) U.S. Trade Representative (USTR) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency, product continuity and issues surrounding medical device reprocessing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Commerce - Dept of (DOC) Food & Drug Administration (FDA)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB) Environmental Protection Agency (EPA) Small Business Administration (SBA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Commerce - Dept of (DOC) Food & Drug Administration (FDA)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, Medline Industries, LP had in-house lobbyists. The report was filed on Jan. 18, 2023.
Original Filing: 301430583.xml
Lobbying Issues
Section 301 tariffs and exclusions
Agencies Lobbied
U.S. Senate U.S. House of Representatives Commerce - Dept of (DOC) White House Office U.S. Trade Representative (USTR)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency and product continuity
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office Commerce - Dept of (DOC)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Commerce - Dept of (DOC) White House Office
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3927 - MADE in America Act regarding strategies to encourage domestic medical product manufacturing
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Medline Industries, LP had in-house lobbyists. The report was filed on Oct. 17, 2022.
Original Filing: 301406197.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency and product continuity
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Medline Industries, LP had in-house lobbyists. The report was filed on July 14, 2022.
Original Filing: 301380154.xml
Lobbying Issues
Section 301 tariffs, exclusions and compliance, S. 1260 United States Innovation and Competition Act of 2021 concerning Section 301 tariffs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency and product continuity; The Medical Supplies for Pandemics Act (H.R. 3463/S.1693) concerning medical product supply chain preparedness; The Strengthening Americas Strategic National Stockpile Act (H.R. 3635/S.1974) concerning medical product supply chain preparedness; Prepare for and Respond to Existing Viruses, Emerging New Threats and Pandemics Act (S.3799) concerning medical product supply chain preparedness.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues regarding medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Medline Industries, LP had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301361712.xml
Lobbying Issues
Section 301 tariffs, exclusions and compliance, S. 1260 United States Innovation and Competition Act of 2021 concerning Section 301 tariffs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain, resiliency and product continuity
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Medline Industries, LP had in-house lobbyists. The report was filed on Jan. 19, 2022.
Original Filing: 301328259.xml
Lobbying Issues
Section 301 tariffs, exclusions and compliance, S. 1260 United States Innovation and Competition Act of 2021 concerning Section 301 tariffs
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Health & Human Services - Dept of (HHS) U.S. Trade Representative (USTR)
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Medline Industries, LP had in-house lobbyists. The report was filed on Oct. 18, 2021.
Original Filing: 301301555.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Healthcare supply chain and resiliency, S. 308 - PPE in America Act regarding strategic national stockpile
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medical device sterilization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Environmental Protection Agency (EPA) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Healthcare supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives State - Dept of (DOS) Health & Human Services - Dept of (HHS) White House Office
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
Medline Industries, LP filed a lobbying registration on Sept. 30, 2021 for in-house lobbying efforts, effective Sept. 30, 2021.
Original Filing: 301296188.xml
Issue(s) they said they’d lobby about: Section 301 tariffs, S. 1260 - United States Innovation and Competition Act of 2021 regarding Section 301 tariffs, medical device sterilization, H.R. 1512 - CLEAN Future Act regarding monitoring, Health care supply chain and resiliency, S. 308 - PPE in America Act regarding strategic national stockpile, H.R. 346 - SUPPLIES Act regarding domestic medical supply production, .
2nd Quarter, 2021
In Q2, Medline Industries, Inc. had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301282387.xml
Lobbying Issues
Section 301 tariffs, S.1260 - United States Innovation and Competition Act of 2021 regarding Section 301 tariffs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Medical device sterilization, H.R.1512 - CLEAN Future Act regarding monitoring
Agencies Lobbied
U.S. House of Representatives U.S. Senate Environmental Protection Agency (EPA)
Lobbying Issues
Health care supply chain and resiliency, S.308 - PPE in America Act regarding strategic national stockpile, H.R.346 - SUPPLIES Act regarding domestic medical supply production
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Health care supply chain and resiliency
Agencies Lobbied
U.S. Senate U.S. House of Representatives State - Dept of (DOS)
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2013
Medline Industries, Inc. in-house lobbying effort was terminated on July 22, 2013
Original Filing: 300582349.xml
Lobbying Issues
Issues related to pharmaceutical supply chain security including H.R. 1919 - Safeguarding America's Pharmaceuticals Act and S. 957 - Drug Supply Chain Security Act; Issues related to the medical device tax, including H.R. 523 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, Medline Industries, Inc. had in-house lobbyists. The report was filed on April 15, 2013.
Original Filing: 300550389.xml
Lobbying Issues
Issues related to the FDA; Issues related to pharmaceutical supply chain security; Issues related to cosmetics; Issues related to the medical device tax, including H.R. 523 - Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
4th Quarter, 2012
In Q4, Medline Industries, Inc. had in-house lobbyists. The report was filed on Jan. 18, 2013.
Original Filing: 300533624.xml
Lobbying Issues
Issues related to the FDA; Issues related to pharmaceutical supply chain security; Issues related to cosmetics, including H.R. 4395 - Cosmetic Safety Amendments Act of 2012 (as well as H.R. 2359 and H.R. 4262); Issues related to the medical device tax, including H.R. 436 - Health Care Cost Reduction Act of 2012 (as well as S. 17 and S. 262).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Medline Industries, Inc. had in-house lobbyists. The report was filed on Oct. 15, 2012.
Original Filing: 300506861.xml
Lobbying Issues
Issues related to the FDA. Issues related to medical devices, including the Unique Device Identification System Proposed Rule; Issues related to pharmaceutical supply chain security; Issues related to cosmetics, including H.R. 4395 - Cosmetic Safety Amendments Act of 2012 (as well as H.R. 2359 and H.R. 4262); Issues related to the medical device tax, including H.R. 436 - Health Care Cost Reduction Act of 2012 (as well as S. 17 and S. 262).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA),
2nd Quarter, 2012
In Q2, Medline Industries, Inc. had in-house lobbyists. The report was filed on July 11, 2012.
Original Filing: 300482703.xml
Lobbying Issues
Issues related to the FDA, including S. 3187 and H.R. 5651- Food and Drug Administration Safety and Innovation Act; Issues related to pharmaceutical supply chain security; Issues related to cosmetics, including H.R. 4395 - Cosmetic Safety Amendments Act of 2012 (as well as H.R. 2359 and H.R. 4262); Issues related to the medical device tax, including H.R. 436 - Health Care Cost Reduction Act of 2012 (as well as S. 17 and S. 262).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Internal Revenue Service (IRS)
2nd Quarter, 2012
Medline Industries, Inc. filed a lobbying registration on July 9, 2012 for in-house lobbying efforts, effective April 1, 2012.
Original Filing: 300481845.xml
Issue(s) they said they’d lobby about: Issues related to the manufacturing and distribution of medical devices, pharmaceuticals, cosmetics, dietary supplements, and foods. Issues related to the manufacturing and distribution of textiles and furniture. Issues related to HHS (including the FDA), the EPA, the CPSC, DHS (including CBP), and USDA. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate